

Samir S Taneja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7606303/publications.pdf>

Version: 2024-02-01

299
papers

14,208
citations

23500

58
h-index

24179

110
g-index

310
all docs

310
docs citations

310
times ranked

10517
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018, 378, 1767-1777.	13.9	2,036
2	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. <i>European Urology</i> , 2015, 68, 1045-1053.	0.9	657
3	Image-Guided Prostate Biopsy Using Magnetic Resonance Imagingâ€‘Derived Targets: A Systematic Review. <i>European Urology</i> , 2013, 63, 125-140.	0.9	479
4	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. <i>European Urology</i> , 2013, 64, 544-552.	0.9	383
5	Complications After Systematic, Random, and Image-guided Prostate Biopsy. <i>European Urology</i> , 2017, 71, 353-365.	0.9	353
6	A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imagingâ€‘Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial. <i>European Urology</i> , 2014, 66, 343-351.	0.9	344
7	Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. <i>Journal of Urology</i> , 2016, 196, 1613-1618.	0.2	305
8	Prostate Cancer Localization Using Multiparametric MR Imaging: Comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert Scales. <i>Radiology</i> , 2013, 269, 482-492.	3.6	237
9	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4066-4072.	0.8	234
10	Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative Chemotherapy. <i>European Urology</i> , 2010, 58, 581-587.	0.9	227
11	Prostate Cancer: Feasibility and Preliminary Experience of a Diffusional Kurtosis Model for Detection and Assessment of Aggressiveness of Peripheral Zone Cancer. <i>Radiology</i> , 2012, 264, 126-135.	3.6	223
12	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. <i>Nature Reviews Urology</i> , 2020, 17, 41-61.	1.9	207
13	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>Radiology</i> , 2020, 296, 76-84.	3.6	207
14	Radiologist, Be Aware: Ten Pitfalls That Confound the Interpretation of Multiparametric Prostate MRI. <i>American Journal of Roentgenology</i> , 2014, 202, 109-120.	1.0	183
15	Optimization of Initial Prostate Biopsy in Clinical Practice: Sampling, Labeling and Specimen Processing. <i>Journal of Urology</i> , 2013, 189, 2039-2046.	0.2	173
16	Robot Assisted Laparoscopic Partial Nephrectomy: Initial Experience. <i>Journal of Urology</i> , 2006, 176, 36-39.	0.2	164
17	Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusionâ€‘targeted Prostate Biopsy Outcomes. <i>European Urology</i> , 2016, 69, 512-517.	0.9	163
18	Optimization of Prostate Biopsy: the Role of Magnetic Resonance Imaging Targeted Biopsy in Detection, Localization and Risk Assessment. <i>Journal of Urology</i> , 2014, 192, 648-658.	0.2	156

#	ARTICLE	IF	CITATIONS
19	Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 706-712.	0.2	152
20	Comparison of Interreader Reproducibility of the Prostate Imaging Reporting and Data System and Likert Scales for Evaluation of Multiparametric Prostate MRI. <i>American Journal of Roentgenology</i> , 2013, 201, W612-W618.	1.0	146
21	Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis. <i>Journal of Urology</i> , 2015, 194, 364-370.	0.2	146
22	Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection. <i>Radiology</i> , 2017, 283, 119-129.	3.6	142
23	Robot-Assisted Laparoscopic Partial Nephrectomy: The NYU Technique. <i>Journal of Endourology</i> , 2005, 19, 441-445.	1.1	138
24	Patient-specific 3D printed and augmented reality kidney and prostate cancer models: impact on patient education. <i>3D Printing in Medicine</i> , 2019, 5, 4.	1.7	121
25	Association Between Combined <i>TPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1085.	3.4	120
26	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1949-1956.	0.8	110
27	Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. <i>BJU International</i> , 2016, 118, 515-520.	1.3	109
28	Prostate Tissue Specificity of the Prostate-Specific Antigen Promoter Isolated from a Patient with Prostate Cancer. <i>Human Gene Therapy</i> , 1995, 6, 1417-1426.	1.4	108
29	Effect of Warm Ischemia Time During Laparoscopic Partial Nephrectomy on Early Postoperative Glomerular Filtration Rate. <i>Journal of Urology</i> , 2009, 181, 2438-2445.	0.2	108
30	Followup Interval Prostate Biopsy 3 Years After Diagnosis of High Grade Prostatic Intraepithelial Neoplasia is Associated With High Likelihood of Prostate Cancer, Independent of Change in Prostate Specific Antigen Levels. <i>Journal of Urology</i> , 2002, 168, 1415-1418.	0.2	104
31	Prostate Cancer: Comparison of 3D T2-Weighted With Conventional 2D T2-Weighted Imaging for Image Quality and Tumor Detection. <i>American Journal of Roentgenology</i> , 2010, 194, 446-452.	1.0	104
32	Computed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection. <i>European Radiology</i> , 2013, 23, 3170-3177.	2.3	102
33	The Learning Curve in Prostate MRI Interpretation: Self-Directed Learning Versus Continual Reader Feedback. <i>American Journal of Roentgenology</i> , 2017, 208, W92-W100.	1.0	102
34	Open Versus Laparoscopic Versus Robot-Assisted Laparoscopic Prostatectomy: The European and US Experience. <i>Reviews in Urology</i> , 2010, 12, 35-43.	0.9	101
35	Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling?. <i>Urology</i> , 2001, 58, 999-1003.	0.5	100
36	Transition Zone Prostate Cancer: Revisiting the Role of Multiparametric MRI at 3 T. <i>American Journal of Roentgenology</i> , 2015, 204, W266-W272.	1.0	89

#	ARTICLE	IF	CITATIONS
37	Length of capsular contact for diagnosing extraprostatic extension on prostate MRI: Assessment at an optimal threshold. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 990-997.	1.9	88
38	AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 832-838.	0.2	88
39	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. <i>Journal of Urology</i> , 2015, 194, 1601-1606.	0.2	87
40	Cell-specific Regulation of Androgen Receptor Phosphorylation in Vivo. <i>Journal of Biological Chemistry</i> , 2005, 280, 40916-40924.	1.6	83
41	Dynamic contrast-enhanced MRI of the prostate with high spatiotemporal resolution using compressed sensing, parallel imaging, and continuous golden-angle radial sampling: Preliminary experience. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1365-1373.	1.9	83
42	Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 694-700.	1.9	82
43	Optimization of Prostate Biopsy. <i>Urologic Clinics of North America</i> , 2014, 41, 299-313.	0.8	79
44	Gleason Score 3+4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1096-1101.	2.1	78
45	ULTRASENSITIVE SERLIM PROSTATE SPECIFIC ANTIGEN NADIR ACCURATELY PREDICTS THE RISK OF EARLY RELAPSE AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 173, 777-780.	0.2	77
46	Impact of Fusion of Indium-111 Capromab Pendetide Volume Data Sets with Those from MRI or CT in Patients with Recurrent Prostate Cancer. <i>American Journal of Roentgenology</i> , 2004, 183, 519-524.	1.0	75
47	Patterns of Repeat Prostate Biopsy in Contemporary Clinical Practice. <i>Journal of Urology</i> , 2015, 193, 1178-1184.	0.2	75
48	Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software. <i>BJU International</i> , 2014, 114, E105-E112.	1.3	74
49	Prostate Cancer: Multiparametric MRI for Index Lesion Localization—A Multiple-Reader Study. <i>American Journal of Roentgenology</i> , 2012, 199, 830-837.	1.0	73
50	Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 708-714.	1.9	71
51	Prebiopsy MRI and MRI-ultrasound Fusion—targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. <i>Urology</i> , 2015, 86, 1192-1199.	0.5	71
52	A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. <i>BJU International</i> , 2007, 99, 395-398.	1.3	67
53	National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses. <i>Urology</i> , 2013, 82, 1283-1290.	0.5	65
54	Prostate Cancer: Diffusion-weighted MR Imaging for Detection and Assessment of Aggressiveness—Comparison between Conventional and Kurtosis Models. <i>Radiology</i> , 2017, 284, 100-108.	3.6	64

#	ARTICLE	IF	CITATIONS
55	The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years. <i>Journal of Urology</i> , 2018, 200, 1022-1029.	0.2	64
56	Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. <i>Urology</i> , 2002, 60, 31-35.	0.5	62
57	Effect of Soy Protein Isolate Supplementation on Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 170.	3.8	62
58	Focal therapy for prostate cancer: The current status. <i>Prostate International</i> , 2015, 3, 35-41.	1.2	61
59	Imaging Facilities' Adherence to PI-RADS v2 Minimum Technical Standards for the Performance of Prostate MRI. <i>Academic Radiology</i> , 2018, 25, 188-195.	1.3	60
60	Standards for prostate biopsy. <i>Current Opinion in Urology</i> , 2014, 24, 155-161.	0.9	58
61	Time-Dependent Diffusion in Prostate Cancer. <i>Investigative Radiology</i> , 2017, 52, 405-411.	3.5	58
62	ART-27, an Androgen Receptor Coactivator Regulated in Prostate Development and Cancer. <i>Journal of Biological Chemistry</i> , 2004, 279, 13944-13952.	1.6	56
63	Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4096-4100.	3.2	55
64	The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. <i>Urology</i> , 2017, 102, 178-182.	0.5	54
65	Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. <i>Clinical Cancer Research</i> , 2003, 9, 2613-9.	3.2	54
66	The role of lymphadenectomy in the surgical management of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 214-223.	0.8	53
67	Prostate Cancer Diagnosis Among Men With Isolated High-Grade Intraepithelial Neoplasia Enrolled Onto a 3-Year Prospective Phase III Clinical Trial of Oral Toremifene. <i>Journal of Clinical Oncology</i> , 2013, 31, 523-529.	0.8	52
68	Prostate Cancer Detection Using Computed Very High b-value Diffusion-weighted Imaging: How High Should We Go?. <i>Academic Radiology</i> , 2016, 23, 704-711.	1.3	52
69	Hand-assisted laparoscopy for large renal specimens: a multi-institutional study. <i>Urology</i> , 2003, 61, 78-82.	0.5	51
70	Prostate cancer: Utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 95-100.	1.9	51
71	Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. <i>Journal of Urology</i> , 2016, 196, 1096-1104.	0.2	51
72	Significance of Pathologic T3a Upstaging in Clinical T1 Renal Masses Undergoing Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 344-349.	0.9	50

#	ARTICLE	IF	CITATIONS
73	Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. <i>Reviews in Urology</i> , 2009, 11, 127-33.	0.9	50
74	Evaluation of a novel precision templateâ€guided biopsy system for detecting prostate cancer. <i>BJU International</i> , 2008, 102, 546-550.	1.3	49
75	Role of MRI in Minimally Invasive Focal Ablative Therapy for Prostate Cancer. <i>American Journal of Roentgenology</i> , 2011, 197, W90-W96.	1.0	49
76	Prostate Cancer: Comparison of Dynamic Contrast-Enhanced MRI Techniques for Localization of Peripheral Zone Tumor. <i>American Journal of Roentgenology</i> , 2013, 201, W471-W478.	1.0	49
77	Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy. <i>European Urology Oncology</i> , 2018, 1, 418-425.	2.6	49
78	Can contemporary transrectal prostate biopsy accurately select candidates for hemiâ€ablative focal therapy of prostate cancer?. <i>BJU International</i> , 2009, 104, 195-199.	1.3	46
79	Prostate Cancer: Comparison of Tumor Visibility on Trace Diffusion-Weighted Images and the Apparent Diffusion Coefficient Map. <i>American Journal of Roentgenology</i> , 2011, 196, 123-129.	1.0	46
80	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1085-1093.	0.2	44
81	Immunotherapy for renal cell carcinoma: The era of interleukin-2-based treatment. <i>Urology</i> , 1995, 45, 911-924.	0.5	42
82	Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy. <i>American Journal of Roentgenology</i> , 2015, 205, 1208-1214.	1.0	42
83	Transperitoneal Laparoscopic Radical Nephrectomy for Large (More Than 7 cm) Renal Masses. <i>Urology</i> , 2008, 71, 421-424.	0.5	41
84	Predicting the outcome of prostate biopsy: comparison of a novel logistic regressionâ€based model, the prostate cancer risk calculator, and prostateâ€specific antigen level alone. <i>BJU International</i> , 2009, 103, 609-614.	1.3	41
85	Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. <i>Urology</i> , 2017, 99, 174-179.	0.5	41
86	Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 222-227.	3.2	40
87	Utility of Diffusional Kurtosis Imaging as a Marker of Adverse Pathologic Outcomes Among Prostate Cancer Active Surveillance Candidates Undergoing Radical Prostatectomy. <i>American Journal of Roentgenology</i> , 2013, 201, 840-846.	1.0	40
88	Androgen Receptor Mutations Identified in Prostate Cancer and Androgen Insensitivity Syndrome Display Aberrant ART-27 Coactivator Function. <i>Molecular Endocrinology</i> , 2005, 19, 2273-2282.	3.7	39
89	Prostate cancer: Utility of diffusionâ€weighted imaging as a marker of sideâ€specific risk of extracapsular extension. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 312-319.	1.9	39
90	Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. <i>Urology</i> , 2018, 112, 112-120.	0.5	36

#	ARTICLE	IF	CITATIONS
91	Prostate Cancer. <i>Journal of Computer Assisted Tomography</i> , 2013, 37, 980-988.	0.5	35
92	Imaging and evaluation of patients with high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 617-628.	1.9	34
93	Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. <i>Journal of Urology</i> , 2012, 188, 2148-2149.	0.2	33
94	A Comparison of Radiologists' and Urologists' Opinions Regarding Prostate MRI Reporting: Results From a Survey of Specialty Societies. <i>American Journal of Roentgenology</i> , 2018, 210, 101-107.	1.0	33
95	The state of prostate MRI in 2013. <i>Oncology</i> , 2013, 27, 262-70.	0.4	32
96	The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 81-86.	0.8	31
97	Does Suspicion of Prostate Cancer on Integrated T2 and Diffusion-weighted MRI Predict More Adverse Pathology on Radical Prostatectomy?. <i>Urology</i> , 2013, 81, 1279-1283.	0.5	31
98	Discriminative Ability of Commonly Used Indexes to Predict Adverse Outcomes After Radical Cystectomy: Comparison of Demographic Data, American Society of Anesthesiologists, Modified Charlson Comorbidity Index, and Modified Frailty Index. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e843-e850.	0.9	31
99	Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2973-2978.	0.8	29
100	High-grade bladder cancer: Association of the apparent diffusion coefficient with metastatic disease: Preliminary results. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 1478-1483.	1.9	29
101	Histopathologic and Clinical Features of Vesical Diverticula. <i>Urology</i> , 2013, 82, 142-147.	0.5	29
102	High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2019, 129, 146-152.	0.5	29
103	Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression. <i>Journal of Cellular Biochemistry</i> , 2002, 84, 188-200.	1.2	28
104	Appropriate Candidates for Hemiablative Focal Therapy Are Infrequently Encountered Among Men Selected for Radical Prostatectomy in Contemporary Cohort. <i>Urology</i> , 2009, 73, 351-354.	0.5	28
105	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	0.9	28
106	Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment. <i>Central European Journal of Urology</i> , 2016, 69, 9-18.	0.2	28
107	Use of Fibrin Glue and Gelfoam to Repair Collecting System Injuries in a Porcine Model: Implications for the Technique of Laparoscopic Partial Nephrectomy. <i>Journal of Endourology</i> , 2003, 17, 799-804.	1.1	27
108	Prostate MRI Can Reduce Overdiagnosis and Overtreatment of Prostate Cancer. <i>Academic Radiology</i> , 2015, 22, 1000-1006.	1.3	27

#	ARTICLE	IF	CITATIONS
109	Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.. Journal of Clinical Oncology, 2021, 39, 4504-4504.	0.8	26
110	Imaging in the diagnosis and management of prostate cancer. Reviews in Urology, 2004, 6, 101-113.	0.9	26
111	Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. Journal of Urology, 2002, 168, 1415-8.	0.2	26
112	Differences in clinicopathologic features of prostate cancer between black and white patients treated in the 1990s and 2000s. Urology, 2006, 67, 120-124.	0.5	25
113	Genome-Wide Impact of Androgen Receptor Trapped clone-27 Loss on Androgen-Regulated Transcription in Prostate Cancer Cells. Cancer Research, 2009, 69, 3140-3147.	0.4	25
114	Utility of MRI Features in Differentiation of Central Renal Cell Carcinoma and Renal Pelvic Urothelial Carcinoma. American Journal of Roentgenology, 2013, 201, 1260-1267.	1.0	25
115	Impact of size of region-of-interest on differentiation of renal cell carcinoma and renal cysts on multi-phase CT: Preliminary findings. European Journal of Radiology, 2014, 83, 239-244.	1.2	25
116	T2-weighted prostate MRI at 7 tesla using a simplified external transmit-receive coil array: Correlation with radical prostatectomy findings in two prostate cancer patients. Journal of Magnetic Resonance Imaging, 2015, 41, 226-232.	1.9	25
117	Clinicopathologic Outcomes of Cystic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 67-70.	0.9	25
118	T2-weighted imaging of the prostate: Impact of the BLADE technique on image quality and tumor assessment. Abdominal Imaging, 2015, 40, 552-559.	2.0	25
119	Likert score 3 prostate lesions: Association between whole-lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy. Journal of Magnetic Resonance Imaging, 2016, 43, 325-332.	1.9	25
120	Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein. Urology, 2001, 57, 202-204.	0.5	24
121	Prediction of Growth Rate of Solid Renal Masses: Utility of MR Imaging Features—Preliminary Experience. Radiology, 2012, 262, 884-893.	3.6	24
122	High temporal resolution 3D gadolinium-enhanced dynamic MR imaging of renal tumors with pharmacokinetic modeling: Preliminary observations. Journal of Magnetic Resonance Imaging, 2013, 38, 802-808.	1.9	24
123	Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29-MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemporary Clinical Trials, 2022, 112, 106618.	0.8	24
124	Laterality Alone Should Not Drive Selection of Candidates for Hemi-Ablative Focal Therapy. Journal of Urology, 2009, 181, 1082-1090.	0.2	23
125	Toremifene — a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion on Investigational Drugs, 2006, 15, 293-305.	1.9	22
126	The role of MRI in prostate cancer diagnosis and management. Future Oncology, 2016, 12, 2431-2443.	1.1	22

#	ARTICLE	IF	CITATIONS
127	Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age. <i>Abdominal Radiology</i> , 2017, 42, 1744-1751.	1.0	22
128	Reduced Field-of-View Diffusion-Weighted Magnetic Resonance Imaging of the Prostate at 3 Tesla: Comparison With Standard Echo-Planar Imaging Technique for Image Quality and Tumor Assessment. <i>Journal of Computer Assisted Tomography</i> , 2017, 41, 949-956.	0.5	22
129	Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1464-1475.	1.9	22
130	A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2001, 91, 2039-2045.	2.0	21
131	Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. <i>Urology</i> , 2002, 60, 10-17.	0.5	21
132	Impact of discordant radiologic and pathologic tumor size on renal cancer staging. <i>Urology</i> , 2006, 68, 728-731.	0.5	21
133	Angiomyolipoma with epithelial cysts: mimic of renal cell carcinoma. <i>Clinical Imaging</i> , 2010, 34, 65-68.	0.8	21
134	Imaging the High-risk Prostate Cancer Patient: Current and Future Approaches to Staging. <i>Urology</i> , 2018, 116, 3-12.	0.5	21
135	Malignant Epithelioid Angiosarcoma of the External Iliac Vein Presenting as Venous Thrombosis. <i>Annals of Vascular Surgery</i> , 2004, 18, 493-496.	0.4	20
136	Candidate Selection for Prostate Cancer Focal Therapy. <i>Journal of Endourology</i> , 2010, 24, 835-841.	1.1	20
137	Long-term Follow-up of Men With Isolated High-grade Prostatic Intra-epithelial Neoplasia Followed by Serial Delayed Interval Biopsy. <i>Urology</i> , 2011, 77, 669-674.	0.5	20
138	Adoption of an Integrated Radiology Reading Room Within a Urologic Oncology Clinic: Initial Experience in Facilitating Clinician Consultations. <i>Journal of the American College of Radiology</i> , 2014, 11, 496-500.	0.9	20
139	Squamous cell carcinoma of the prostate. <i>Reviews in Urology</i> , 2011, 13, 56-60.	0.9	20
140	Robot-assisted laparoscopic partial nephrectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2005, 9, 83-6.	0.5	19
141	Transcriptional Regulation of the Androgen Receptor Cofactor Androgen Receptor Trapped Clone-27. <i>Molecular Endocrinology</i> , 2007, 21, 2864-2876.	3.7	18
142	Apparent Diffusion Coefficient Values of Prostate Cancer: Comparison of 2D and 3D ROIs. <i>American Journal of Roentgenology</i> , 2018, 210, 113-117.	1.0	18
143	Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram. <i>European Urology Focus</i> , 2019, 5, 815-822.	1.6	18
144	Lymph node dissection during the surgical treatment of renal cancer in the modern era. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2008, 34, 132-142.	0.7	17

#	ARTICLE	IF	CITATIONS
145	The effect of changes in Medicare reimbursement on the practice of office and hospital-based endoscopic surgery for bladder cancer. <i>Cancer</i> , 2010, 116, 1264-1271.	2.0	17
146	Imaging of prostate cancer: a platform for 3D co-registration of in-vivo MRI ex-vivo MRI and pathology. <i>Proceedings of SPIE</i> , 2012, 8316, 83162M.	0.8	17
147	Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA TM , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study. <i>BJU International</i> , 2012, 109, 1770-1775.	1.3	17
148	Testosterone in prostate cancer: the Bethesda consensus. <i>BJU International</i> , 2012, 110, 344-352.	1.3	17
149	Complex cystic renal masses: Comparison of cyst complexity and Bosniak classification between 1.5T and 3T MRI. <i>European Journal of Radiology</i> , 2014, 83, 503-508.	1.2	17
150	Using multiparametric MRI to "personalize" biopsy for men. <i>Current Opinion in Urology</i> , 2015, 25, 498-503.	0.9	17
151	Novel Use of Fluorescence Lymphangiography During Robotic Groin Dissection for Penile Cancer. <i>Urology</i> , 2017, 107, 267.	0.5	17
152	Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment. <i>Cancer</i> , 2012, 118, 3145-3152.	2.0	16
153	Maximal Testosterone Suppression in Prostate Cancer-Free vs Total Testosterone. <i>Urology</i> , 2014, 83, 1217-1222.	0.5	16
154	Use of a Quality Improvement Initiative to Achieve Consistent Reporting of Level of Suspicion for Tumor on Multiparametric Prostate MRI. <i>American Journal of Roentgenology</i> , 2016, 206, 1040-1044.	1.0	16
155	Followup of Men with PI-RADS ₂ , 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. <i>Journal of Urology</i> , 2021, 205, 748-754.	0.2	16
156	A workflow to generate patient-specific three-dimensional augmented reality models from medical imaging data and example applications in urologic oncology. <i>3D Printing in Medicine</i> , 2021, 7, 34.	1.7	16
157	Focal therapy: a new paradigm for the treatment of prostate cancer. <i>Reviews in Urology</i> , 2009, 11, 203-12.	0.9	16
158	Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. <i>Urology</i> , 2005, 65, 942-946.	0.5	15
159	3.0 T multiparametric prostate MRI using pelvic phased-array coil: Utility for tumor detection prior to biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1430-1435.	0.8	15
160	Impact of Socioeconomic Factors on Prostate Cancer Outcomes in Black Patients Treated with Surgery. <i>Urology</i> , 2008, 72, 641-646.	0.5	14
161	Association between changes in suspicious prostate lesions on serial MRI examinations and follow-up biopsy results. <i>Clinical Imaging</i> , 2015, 39, 264-269.	0.8	14
162	Practical Barriers to Obtaining Pre-Biopsy Prostate MRI: Assessment in Over 1,500 Consecutive Men Undergoing Prostate Biopsy in a Single Urologic Practice. <i>Urologia Internationalis</i> , 2016, 97, 247-248.	0.6	14

#	ARTICLE	IF	CITATIONS
163	The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance. <i>Abdominal Radiology</i> , 2017, 42, 2340-2345.	1.0	14
164	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. <i>BMJ Open</i> , 2017, 7, e017863.	0.8	14
165	Online Interactive Case-Based Instruction in Prostate Magnetic Resonance Imaging Interpretation Using Prostate Imaging and Reporting Data System Version 2: Effect for Novice Readers. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 132-141.	0.6	14
166	Prostate MR Imaging. <i>Radiologic Clinics of North America</i> , 2017, 55, 303-320.	0.9	13
167	Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort—How Many Clinically Significant Prostate Cancers are Missed?. <i>Journal of Urology</i> , 2021, 205, 740-747.	0.2	13
168	Partial Nephrectomy: Contemporary Outcomes, Candidate Selection, and Surgical Approach. <i>Urologic Clinics of North America</i> , 2012, 39, 199-210.	0.8	12
169	Renal masses measuring under 2cm: Pathologic outcomes and associations with MRI features. <i>European Journal of Radiology</i> , 2014, 83, 1311-1316.	1.2	12
170	Use of Reduced Field-of-View Acquisition to Improve Prostate Cancer Visualization on Diffusion-Weighted Magnetic Resonance Imaging in the Presence of Hip Implants: Report of 2 Cases. <i>Current Problems in Diagnostic Radiology</i> , 2018, 47, 125-127.	0.6	12
171	Prostate Cancers Detected by Magnetic Resonance Imaging—Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 86-91.	1.2	12
172	Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?. <i>Urology</i> , 2002, 60, 36-41.	0.5	11
173	Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. <i>Urology</i> , 2003, 62, 1058-1062.	0.5	11
174	Prostate-specific Antigen Testing and Prostate Cancer Screening. <i>Primary Care - Clinics in Office Practice</i> , 2010, 37, 441-459.	0.7	11
175	Different models for prediction of radical cystectomy postoperative complications and care pathways. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721987558.	0.9	11
176	Prostate biopsy: targeting cancer for detection and therapy. <i>Reviews in Urology</i> , 2006, 8, 173-82.	0.9	11
177	Is surveillance of small renal masses safe in the elderly?. <i>BJU International</i> , 2010, 105, 1098-1101.	1.3	10
178	Quantitative Graphical Analysis of Simultaneous Dynamic PET/MRI For Assessment of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, e236-e240.	0.7	10
179	Implementation of Multi-parametric Prostate MRI in Clinical Practice. <i>Current Urology Reports</i> , 2015, 16, 56.	1.0	10
180	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020, 61, 552-562.	2.8	10

#	ARTICLE	IF	CITATIONS
181	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 781.e17-781.e24.	0.8	10
182	Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 519-528.	2.6	10
183	Pilot study of a novel tool for input-free automated identification of transition zone prostate tumors using T2 and diffusion-weighted signal and textural features. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 301-305.	1.9	9
184	Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy. <i>Urologic Clinics of North America</i> , 2017, 44, 535-546.	0.8	9
185	Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches. <i>World Journal of Urology</i> , 2019, 37, 419-427.	1.2	9
186	Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy. <i>Reviews in Urology</i> , 2009, 11, 33-7.	0.9	9
187	Volume-specific cutoffs are necessary for reproducible application of prostate-specific antigen density of the transition zone in prostate cancer detection. <i>Urology</i> , 2001, 58, 222-226.	0.5	8
188	A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. <i>Anti-Cancer Drugs</i> , 2003, 14, 67-72.	0.7	8
189	Preoperative renal tumor evaluation by three-dimensional magnetic resonance imaging: Staging and detection of multifocality. <i>Urology</i> , 2004, 64, 453-457.	0.5	8
190	Creation of Urinary Stoma Before Abdominal Wall Transposition of Ileal Conduit Improves Stomal Protrusion, Eversion, and Symmetry. <i>Urology</i> , 2009, 73, 893-895.	0.5	8
191	Simplified Reconstruction After Laparoscopic Partial Nephrectomy Using a Single-Pass Suturing Technique. <i>Journal of Endourology</i> , 2009, 23, 589-592.	1.1	8
192	Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor After Transurethral Resection for Bladder Cancer. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 201-205.	0.5	8
193	A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 3.e1-3.e8.	0.8	8
194	HistoScanning™ to Detect and Characterize Prostate Cancer—a Review of Existing Literature. <i>Current Urology Reports</i> , 2017, 18, 97.	1.0	8
195	Influence of renal biopsy results on the management of small kidney cancers in older patients: Results from a population-based cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e1-604.e9.	0.8	8
196	Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. <i>Abdominal Radiology</i> , 2017, 42, 346-349.	1.0	8
197	Prospects for gene therapy in human prostate cancer. <i>Trends in Molecular Medicine</i> , 1998, 4, 494-504.	2.6	7
198	Laparoscopic and Open Partial Nephrectomy: Frequency and Long-term Follow-up of Postoperative Collections. <i>Radiology</i> , 2010, 255, 476-484.	3.6	7

#	ARTICLE	IF	CITATIONS
199	Comparison of CT-Based Methodologies for Detection of Growth of Solid Renal Masses on Active Surveillance. American Journal of Roentgenology, 2012, 199, 373-378.	1.0	7
200	Targeted Prostate Biopsy: Opportunities and Challenges in the Era of Multiparametric Prostate Magnetic Resonance Imaging. Journal of Urology, 2012, 188, 1072-1073.	0.2	7
201	Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition. Abdominal Radiology, 2017, 42, 290-297.	1.0	7
202	3D Registration of mpMRI for Assessment of Prostate Cancer Focal Therapy. Academic Radiology, 2017, 24, 1544-1555.	1.3	7
203	Role of prostate magnetic resonance imaging in active surveillance. Translational Andrology and Urology, 2017, 6, 444-452.	0.6	7
204	Effect of Malnutrition on Radical Nephroureterectomy Morbidity and Mortality: Opportunity for Preoperative Optimization. Clinical Genitourinary Cancer, 2018, 16, e807-e815.	0.9	7
205	The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (<scp>MRI</scp>) predict the likelihood of clinically significant cancer on <scp>MRI</scp>â€“ultrasound fusionâ€“targeted biopsy. BJU International, 2019, 123, 439-446.	1.3	7
206	Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer. Clinical Genitourinary Cancer, 2019, 17, e123-e129.	0.9	7
207	Making a case â€œforâ€“focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials. World Journal of Urology, 2021, 39, 729-739.	1.2	7
208	MP67-14 PREDICTIVE VALUE OF NEGATIVE 3T MULTIPARAMETRIC PROSTATE MRI ON 12 CORE BIOPSY RESULTS. Journal of Urology, 2014, 191, .	0.2	6
209	Role of MRI prebiopsy in men at risk for prostate cancer. Current Opinion in Urology, 2017, 27, 246-253.	0.9	6
210	MRI-fusion biopsy: the contemporary experience. Translational Andrology and Urology, 2017, 6, 483-489.	0.6	6
211	Targeting prostate cancer for focal destruction. Cancer, 2008, 113, 1500-1501.	2.0	5
212	Laparoscopic Partial Nephrectomy: Technique and Outcomes. Current Urology Reports, 2010, 11, 1-7.	1.0	5
213	Integrating MRI for the diagnosis of prostate cancer. Current Opinion in Urology, 2016, 26, 466-471.	0.9	5
214	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. Journal of Urology, 2016, 195, 926-927.	0.2	4
215	Editorial: Refining the Gold Standard-Can We Do Better With Serum Prostate Specific Antigen in the Detection of Prostate Cancer?. Journal of Urology, 1997, 157, 1752-1753.	0.2	3
216	Focal therapy for prostate cancer â€“ where are we in 2011?. Therapeutic Advances in Urology, 2011, 3, 183-192.	0.9	3

#	ARTICLE	IF	CITATIONS
217	MP86-03 PREDICTION OF OVERALL AND CLINICALLY SIGNIFICANT CANCER RISK ON MRI-TARGETED AND SYSTEMATIC PROSTATE BIOPSY USING PREBIOPSY NOMOGRAMS. <i>Journal of Urology</i> , 2015, 193, .	0.2	3
218	MP53-11 A PRE-BIOPSY NOMOGRAM FOR PREDICTION OF THE RISK OF GLEASON SCORE = 7 PROSTATE CANCER ON COMBINED MRI-US FUSION TARGETED AND SYSTEMATIC PROSTATE BIOPSY AMONG MEN WITH NO PREVIOUS BIOPSY. <i>Journal of Urology</i> , 2016, 195, .	0.2	3
219	Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, xv-xvi.	0.8	3
220	Re: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>Journal of Urology</i> , 2018, 200, 697-699.	0.2	3
221	Magnetic resonance imaging in prostate cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 343-344.	0.6	3
222	Grading variability of urothelial carcinoma: experience from a single academic medical center. <i>Canadian Journal of Urology</i> , 2014, 21, 7374-8.	0.0	3
223	Phytoestrogens and prostate cancer: possible preventive role. <i>Medical Journal of Australia</i> , 1998, 168, 467-467.	0.8	2
224	Evolving Treatment Paradigms for Renal Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, xiii-xiv.	0.8	2
225	Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, 122-123.	0.2	2
226	Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. <i>Urologic Clinics of North America</i> , 2016, 43, xiii-xiv.	0.8	2
227	Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 1265-1266.	0.2	2
228	Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study. <i>Journal of Urology</i> , 2017, 198, 101-102.	0.2	2
229	Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial. <i>Journal of Urology</i> , 2017, 198, 255-257.	0.2	2
230	Re: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 342-343.	0.2	2
231	Reply. <i>Urology</i> , 2018, 112, 120.	0.5	2
232	ACR Stakeholder Prostate Summit. <i>Journal of the American College of Radiology</i> , 2020, 17, 1068-1070.	0.9	2
233	Re: Ten-Year Mortality, Disease Progression, and Treatment-Related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>Journal of Urology</i> , 2020, 203, 882-883.	0.2	2
234	Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. <i>Reviews in Urology</i> , 2003, 5, 149-55.	0.9	2

#	ARTICLE	IF	CITATIONS
235	Comparison of Prostate Imaging and Reporting Data System V2.0 and V2.1 for Evaluation of Transition Zone Lesions: A 5-Reader 202-Patient Analysis. <i>Journal of Computer Assisted Tomography</i> , 2022, 46, 523-529.	0.5	2
236	Machine learning decision support model for radical cystectomy discharge planning. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 453.e9-453.e18.	0.8	2
237	Re: Age Adjusted Prostate Specific Antigen and Prostate Specific Antigen Velocity Cut Points in Prostate Cancer Screening. <i>European Urology</i> , 2007, 52, 607.	0.9	1
238	Focal therapy in urologic oncology: maximizing organ function and oncologic disease control. <i>World Journal of Urology</i> , 2010, 28, 549-550.	1.2	1
239	Re: Incidence of Downstaging and Complete Remission After Neoadjuvant Chemotherapy for High-Risk Upper Tract Transitional Cell Carcinoma. <i>Journal of Urology</i> , 2011, 185, 807-807.	0.2	1
240	Unilateral Adenocarcinoma and High-Grade Prostatic Intraepithelial Neoplasia in Prostatectomies: Possible Implication for Patient Care. <i>American Journal of Clinical Pathology</i> , 2012, 138, A110-A110.	0.4	1
241	Foreword. <i>Urologic Clinics of North America</i> , 2012, 39, xi-xii.	0.8	1
242	Recent Developments in Multiparametric Prostate MR Imaging. <i>Current Radiology Reports</i> , 2014, 2, 1.	0.4	1
243	Re: Diffusion-Weighted MR Imaging in Early Assessment of Tumor Response to Radiotherapy in High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 539-540.	0.2	1
244	Management of High Grade Bladder Cancer: A Multidisciplinary Approach. <i>Urologic Clinics of North America</i> , 2015, 42, xi-xii.	0.8	1
245	Focal Therapy for Prostate Cancer. , 2016, , 563-577.		1
246	Re: Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy. <i>Journal of Urology</i> , 2016, 196, 1819-1819.	0.2	1
247	Penile, Urethral, and Scrotal Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, xv-xvi.	0.8	1
248	Re: Prostate Cancer Detection with Magnetic Resonance-Ultrasound Fusion Biopsy: The Role of Systematic and Targeted Biopsies. <i>Journal of Urology</i> , 2016, 196, 101-102.	0.2	1
249	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply.. <i>Journal of Urology</i> , 2021, 205, 1528-1529.	0.2	1
250	Urologic Imaging. , 2020, , 201-256.		1
251	PROSTATE BIOPSY OUTCOME PREDICTION – COMPARISON OF A NOVEL LOGISTIC REGRESSION-BASED MODEL, THE PROSTATE CANCER RISK CALCULATOR AND PSA ALONE. <i>Journal of Urology</i> , 2008, 179, 640-641.	0.2	0
252	Positive surgical margins at radical prostatectomy: Do they really matter?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 195-196.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Proceeding of the 2009 Society of Urologic Oncology Spring Meeting. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 541.	0.8	0
254	Urological Oncology: Renal, Ureteral and Retroperitoneal Tumors. Journal of Urology, 2011, 186, 1394-1394.	0.2	0
255	Specialty Imaging: Genitourinary Oncology Shaaban A.M., Blodgett T.M., Rezvani M. and Bauer D.: Specialty Imaging: Genitourinary Oncology. Philadelphia: Lippicott Williams & Wilkins 2010. 148 pages.. Journal of Urology, 2012, 187, 769-769.	0.2	0
256	Foreword. Urologic Clinics of North America, 2012, 39, xiii.	0.8	0
257	The Contemporary Ambulatory Urologic Practice. Urologic Clinics of North America, 2013, 40, xi.	0.8	0
258	Foreword. Urologic Clinics of North America, 2013, 40, xi.	0.8	0
259	Foreword. Urologic Clinics of North America, 2013, 40, xi.	0.8	0
260	Foreword. Urologic Clinics of North America, 2013, 40, xi.	0.8	0
261	Urodynamics. Urologic Clinics of North America, 2014, 41, xi.	0.8	0
262	Advances in Robotic-Assisted Urologic Surgery. Urologic Clinics of North America, 2014, 41, xv-xvi.	0.8	0
263	Current Management of Male Infertility. Urologic Clinics of North America, 2014, 41, xv.	0.8	0
264	Early Detection of Prostate Cancer. Urologic Clinics of North America, 2014, 41, xi-xii.	0.8	0
265	Re: Docetaxel and Atrasentan versus Docetaxel and Placebo for Men with Advanced Castration-Resistant Prostate Cancer (SWOG S0421): A Randomised Phase 3 Trial. Journal of Urology, 2014, 191, 656-658.	0.2	0
266	Testicular Cancer. Urologic Clinics of North America, 2015, 42, xv.	0.8	0
267	Magnetic Resonance Sentinel Lymph Node Detection in Prostate Cancer. Academic Radiology, 2015, 22, 545-547.	1.3	0
268	Contemporary Antibiotic Management for Urologic Procedures and Infections. Urologic Clinics of North America, 2015, 42, xiii.	0.8	0
269	Minimally Invasive Pediatric Urologic Surgery. Urologic Clinics of North America, 2015, 42, xiii.	0.8	0
270	Editorial Comment. Journal of Urology, 2016, 196, 365-365.	0.2	0

#	ARTICLE	IF	CITATIONS
271	Re: Gleason Misclassification Rate is Independent of Number of Biopsy Cores in Systematic Biopsy. Journal of Urology, 2016, 196, 413-414.	0.2	0
272	Hypogonadism. Urologic Clinics of North America, 2016, 43, xv.	0.8	0
273	Biomarkers in Urologic Cancer. Urologic Clinics of North America, 2016, 43, xv.	0.8	0
274	Small Renal Mass. Urologic Clinics of North America, 2017, 44, xv.	0.8	0
275	The Impact of Neurologic Disease on the Urinary Tract. Urologic Clinics of North America, 2017, 44, xv.	0.8	0
276	Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. Journal of Urology, 2017, 198, 743-744.	0.2	0
277	Novel risk stratification nomograms for counseling patients on the need for prostate biopsy. BJU International, 2017, 120, 746-747.	1.3	0
278	Re: Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. Journal of Urology, 2018, 199, 609-610.	0.2	0
279	Re-Creating the Urinary Tract: An Art Derived from Science. Urologic Clinics of North America, 2018, 45, xv.	0.8	0
280	Editorial Comment. Journal of Urology, 2018, 200, 792-792.	0.2	0
281	Advances in Urologic Imaging. Urologic Clinics of North America, 2018, 45, xv.	0.8	0
282	Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Journal of Urology, 2018, 200, 699-699.	0.2	0
283	Evaluation and Treatment for Older Men with Elevated PSA. , 2018, , 21-41.		0
284	Gender Reassignment Surgery: A New Frontier for Urologists. Urologic Clinics of North America, 2019, 46, xiii.	0.8	0
285	Reconstruction of the Female Pelvis: A Fundamental Pillar of Urology. Urologic Clinics of North America, 2019, 46, xv.	0.8	0
286	Urological Oncology: Prostate Cancer. Journal of Urology, 2021, 205, 629-631.	0.2	0
287	Urological Oncology: Prostate Cancer. Journal of Urology, 2021, 205, 1823-1825.	0.2	0
288	Urological Oncology: Prostate Cancer. Journal of Urology, 2021, 206, 158-161.	0.2	0

#	ARTICLE	IF	CITATIONS
289	Urological Oncology: Prostate Cancer. Journal of Urology, 2021, 206, 476-479.	0.2	0
290	Urological Oncology: Prostate Cancer. Journal of Urology, 2021, 206, 772-774.	0.2	0
291	Multiparametric MRI of the Prostate as a Tool for Prostate Cancer Detection, Localization, and Risk Assessment. , 2016, , 107-126.		0
292	Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment AUTHOR'S REPLY. Central European Journal of Urology, 2016, 69, 24.	0.2	0
293	Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial. Journal of Urology, 2019, 202, 32-33.	0.2	0
294	Re: Use of Prostate Systematic and Targeted Biopsy on the Basis of Multiparametric MRI in Biopsy-Naive Patients (MRI-FIRST): A Prospective, Multicentre, Paired Diagnostic Study. Journal of Urology, 2019, 202, 34-35.	0.2	0
295	Re: Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-Institutional Prospective Study. Journal of Urology, 2019, 202, 31-32.	0.2	0
296	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.2	0
297	Management of prostate cancer: NYU Case of the Month, July 2017. Reviews in Urology, 2017, 19, 180-184.	0.9	0
298	Transperineal Saturation Prostate Biopsy: NYU Case of the Month, March 2019. Reviews in Urology, 2019, 21, 35-40.	0.9	0
299	Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy. Canadian Journal of Urology, 2009, 16, 4655-9.	0.0	0